KPV (Lysine–Proline–Valine) – 10mg

KPV (10mg) — Research Compound

KPV is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). It is studied for its potent anti-inflammatory and antimicrobial properties, functioning through the modulation of the NF-κB signaling pathway. Researchers investigate KPV for its ability to reduce pro-inflammatory cytokine production without the systemic effects associated with larger melanocortin peptides. It is a primary focus for studies involving gut health, inflammatory bowel conditions, and dermal wound repair.

Findings from early-stage clinical trials have reported:

• Significant reductions in the expression of pro-inflammatory cytokines such as TNF-α and IL-1β observed in research models
  
• Improved healing of intestinal mucosal tissue reported in experimental models of colitis
  
• Reductions in skin inflammation and itching noted in-vivo across various study groups
  
• Broad-spectrum antimicrobial effects against common pathogens reported in cellular research
  

Researchers utilize KPV to investigate the regulation of inflammatory responses at the cellular level. Its small molecular size and high stability make it a unique tool for studying localized immune modulation and the biological mechanisms of tissue protection. It is a focal point for research into chronic inflammatory disorders and the development of non-steroidal therapeutic models for autoimmune regulation.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use